Clinical Trials Browser

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Fractures, Bone

Humoral Hypercalcemia Of Malignancy, Breast Neoplasms, Neoplasm Metastasis, Pain, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Bone Diseases, Metabolic, Breast Neoplasms

Breast Neoplasms, Multiple Myeloma

Breast Neoplasms, Fatigue

Breast Neoplasms

Breast Neoplasms, Carcinoma, Ductal, Breast

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neovascularization, Pathologic

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Multiple Myeloma, Pain, Prostatic Neoplasms

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Bone Diseases, Breast Neoplasms

Breast Neoplasms, Pain

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Pain, Prostatic Neoplasms

Breast Neoplasms, Prostatic Neoplasms

Breast Neoplasms, Osteoporosis

Breast Neoplasms, Osteoporosis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Osteoporosis

Humoral Hypercalcemia Of Malignancy, Breast Neoplasms, Neoplasm Metastasis, Pain

Breast Neoplasms, Neoplasm Micrometastasis

Breast Neoplasms, Neoplasm Metastasis

Humoral Hypercalcemia Of Malignancy, Breast Neoplasms, Neoplasm Metastasis, Pain

Breast Neoplasms

Breast Neoplasms, Osteoporosis

Humoral Hypercalcemia Of Malignancy, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Bone Diseases, Metabolic, Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Multiple Myeloma, Pain, Prostatic Neoplasms

Breast Neoplasms, Osteoporosis

Breast Neoplasms

Clinical Trials

REaCT-ZOL

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

HOBOE

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole

Study on Bisphosphonates Targeting Triple-negative Breast Cancer

S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.

BLAZE

Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year

PBCB

Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

NEO-ZOTAC

Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer

NEOZOL

Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)

ER11-03

ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer

Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases

Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer

Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer

Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer

Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

NATAN

A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss

Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer

CTIBL

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone

Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer

Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer

Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density

Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer

Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer

Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole